Open AccessPulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report
Author(s) -
Ghina Fakhri,
Reem Akel,
Ziad Salem,
Ayman Tawil,
Arafat Tfayli
Publication year - 2017
Publication title -
case reports in oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.365
H-Index - 19
ISSN - 1662-6575
DOI - 10.1159/000484596
Subject(s) - medicine , pembrolizumab , sarcoidosis , chemotherapy , lung cancer , oncology , neoadjuvant therapy , pulmonary sarcoidosis , lung , cancer , radiology , immunotherapy , breast cancer
Pembrolizumab is a humanized monoclonal antibody which serves to enhance the antitumor immune response by targeting programmed cell death 1 receptor. The use of pembrolizumab plus carboplatin/pemetrexed combination therapy results in improvement in overall survival and progression-free survival rates for non-small cell lung cancer (NSCLC) patients as compared to chemotherapy alone. However, numerous immune-mediated toxicities of pembrolizumab have been reported.